 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning Amersham Biosciences Europe GmbH
|
-
Amersham: New study using Ettan DIGE technology reveals significant results
(24 Mar 2004)
A new study published in Proteomics1 shows that two-dimensional difference gel electrophoresis (2-D DIGE) technology provided by Amersham Biosciences, the life sciences business of Amersham, reveals statistically significant differences in protein ...
-
Amersham Biosciences broadens range of cellular analysis solutions with Guava Technologies' Japan distribution deal
(25 Feb 2004)
Amersham Biosciences, the life sciences business of Amersham, has signed an exclusive three-year distribution agreement covering the territory of Japan with Guavaź Technologies, Inc for Guava Personal Cell Analysis (PCA) systems, reagents and ...
-
Amersham and Bayer Diagnostics sign exclusive development and supply agreement for diagnostic sequencing
(17 Feb 2004)
London, UK and Tarrytown, NY - Amersham and the Diagnostics Division of Bayer HealthCare LLC, a member of the Bayer Group ("Bayer"), announced they have entered into an exclusive worldwide agreement for joint development of assays and ...
-
Amersham plc appoints Peter Loescher as Chief Operating Officer
(17 Nov 2003)
Amersham plc announced the appointment of Peter Loescher to the role of Chief Operating Officer, effective 1 January 2004. Mr Loescher, 46, joined the company in December 2002 as President of Amersham Health and an Executive member of the Amersham ...
-
Lilly Complements its Drug Discovery Research with Integrated Cellular Screening System from Amersham Biosciences
(11 Nov 2003)
Amersham, a world leader in medical diagnostics and in life sciences, announces that Eli Lilly and Company has purchased an integrated suite of cellular screening technology and licenses to help in the identification of potential therapeutics in its ...
-
Amersham Biosciences and GeneBio expand alliance to develop next generation proteomics image analysis software
(23 Jul 2003)
Agreement expands the strategic alliance between the two companies signed in January 2003 to develop and distribute novel proteomics analysis software, databases and training tools
Amersham Biosciences, the life sciences business of Amersham and Geneva Bioinformatics S.A. have signed an exclusive agreement to provide researchers with the next generation of 2-D gel image analysis tools for proteomics research.This collaboration ...
Additional information
Amersham Biosciences Europe GmbH
Freiburg, Germany
Articles
|
|
|
|
|
|
Top
